Clinical Trials Logo

Metformin clinical trials

View clinical trials related to Metformin.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06125587 Enrolling by invitation - Clinical trials for Polycystic Ovary Syndrome

Chiglitazar/Metformin in Non-obese Women With PCOS

Start date: November 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorders in women of reproductive age, and its prevalence rate is from 9% (NIH criteria) to 18% (Rotterdamcriteria). It is clinically characterized by hyperandrogenism, persistent anovulation, and polycystic ovarian changes. Moreover it is often accompanied by insulin resistance and obesity. Now, metformin is not only an antihyperglycemic drug, it also corrects insulin resistance and hyperandrogenism in polycystic ovary syndrome. Chiglitazar is a novel peroxisome proliferation activated receptor (PPAR) agonist. Treatment of type 2 diabetes mellitus by moderate activation of PPARα, PPARγ and PPARδ, improving insulin sensitivity, regulating blood glucose, and promoting fatty acid oxidation and utilization. However, there is limited evidence for its treatment of insulin resistance in women with PCOS. Therefore, we applied chiglitazar and metformin to two groups of PCOS patients to understand their effects on insulin resistance.

NCT ID: NCT05900284 Enrolling by invitation - Sepsis Clinical Trials

Safety and Feasibility of Metformin for Sepsis Induced AKI

Start date: November 8, 2023
Phase: Phase 2
Study type: Interventional

Acute kidney injury (AKI) is an independent risk factor for death that affects 10-15% of hospitalized patients and more than 50% of patients admitted to the intensive care unit. Sepsis is the most frequent cause of AKI, affecting 48 million people worldwide every year, and accounting for approximately 11 million of annual global deaths. Despite these figures, there are no known therapies to prevent or reverse septic AKI; hence this study aims to establish the safety and feasibility of the implementation of metformin in the treatment of AKI in patients with sepsis. This study is the first critical step to inform the design of a future, full-scale efficacy randomized clinical trial.